CNSP Stock Price | Cns Pharmaceuticals Inc P/E, Revenue, EPS, & Forecasts

Cns Pharmaceuticals Inc • CNSP

Capital at risk.

About
Metrics
Forecasts
Earnings performance
Financial performance
Sentiment analysis
FAQs

About Cns Pharmaceuticals Inc

Ticker

CNSP

Trading on

NASDAQ

ISIN

US18978H1023

Industry

Biotechnology

Sector

Healthcare

CEO

John Michael Climaco Esq., J.D.

Headquarters

2100 West Loop South, Houston, TX, United States, 77027

Employees

Website

cnspharma.com

CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. CNS Pharmaceuticals, Inc. has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D. Anderson Cancer Center, as well as a collaboration and asset purchase agreement with Reata Pharmaceuticals, Inc. The company was incorporated in 2017 and is based in Houston, Texas.

Metrics

BasicAdvanced

Market cap

$3.1M

P/E ratio

EPS

-$1,943.50

Dividend Yield

0.00%

Beta

1.08

Forward P/E ratio

EBIDTA

$-14.9M

Ex dividend date

Price & volume

Market cap

$3.1M

Average daily volume

0.2M

90-day return

30-day return

7-day return

Dividends

Dividend per share

$0.00

Dividend yield

0.00%

Forward dividend per share

$0.00

Forward dividend yield

0.00%

Payout ratio

0.00%

Valuation

P/E ratio

Forward P/E

PEG ratio

Trailing P/E

Price to sales

Price to book

0.5

Earnings

EPS

-$1,943.50

EPS estimate (current quarter)

-$0.10

EPS estimate (next quarter)

$0.00

EBITDA

$-14.9M

Revenues (TTM)

$0M

Revenues per share (TTM)

$0.00

Technicals

Beta

1.08

52-week High

$414.00

52-week Low

$0.77

50-day moving average

$2.24

200-day moving average

$8.72

Short ratio

0.91

Short %

11.00%

Management effectiveness

ROE (TTM)

1,703.39%

ROA (TTM)

179.08%

Profit margin

0.00%

Gross profit margin

$0M

Operating margin

0.00%

Growth

Quarterly earnings growth (YoY)

0.00%

Quarterly revenue growth (YoY)

0.00%

Share stats

Outstanding Shares

2.9M

Float

2.9M

Insiders %

0.40%

Institutions %

2.40%

Analyst Insights & forecasts

50% Buy

50% Hold

0% Sell

Based on information from 2 analysts.

Average price target

$200.00

Earnings per share (EPS) forecast

windowbar_chart_4_bars

Actual

Expected

Surprise

-$0.41

Q1 • 24Beat

-$6.72

Q2 • 24Beat

-$0.25

-$0.10

152.70%

Q3 • 24Beat

-$37.33

-$7.33

409.28%

Q4 • 24Beat

-$2.25

Q1 • 25Current

QuarterlyAnnual

Financial Performance

windowbar_chart_4_bars

Income StatementBalance SheetCash Flow

windowbar_chart_4_bars

Revenue

Net income

Profit margin

$0M

$-5.6M

∞%

Q3 • 24

$0M

$-3.2M

∞%

Q4 • 24

NaN%

43.34%

NaN%

QoQ growth

QuarterlyAnnual

Totals assets

Total liabilities

Debt to assets

$7.4M

$4.1M

54.75%

Q3 • 24

$8.7M

$2.5M

29.01%

Q4 • 24

17.43%

37.78%

47.01%

QoQ growth

QuarterlyAnnual

Operating

Investing

Financing

Free cash flow

$-6.8M

$12.3M

$-6.8M

Q3 • 24

$-5.5M

$-0M

$5M

$-5.5M

Q4 • 24

19.55%

59.59%

19.48%

QoQ growth

QuarterlyAnnual

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a Cns Pharmaceuticals Inc share?

Cns Pharmaceuticals Inc shares are currently traded for undefined per share.

How many shares does Cns Pharmaceuticals Inc have?

Cns Pharmaceuticals Inc currently has 2.9M shares.

Does Cns Pharmaceuticals Inc pay dividends?

No, Cns Pharmaceuticals Inc doesn't pay dividends.

What is Cns Pharmaceuticals Inc 52 week high?

Cns Pharmaceuticals Inc 52 week high is $414.00.

What is Cns Pharmaceuticals Inc 52 week low?

Cns Pharmaceuticals Inc 52 week low is $0.77.

What is the 200-day moving average of Cns Pharmaceuticals Inc?

Cns Pharmaceuticals Inc 200-day moving average is $8.72.

Who is Cns Pharmaceuticals Inc CEO?

The CEO of Cns Pharmaceuticals Inc is John Michael Climaco Esq., J.D..

How many employees Cns Pharmaceuticals Inc has?

Cns Pharmaceuticals Inc has 4 employees.

What is the market cap of Cns Pharmaceuticals Inc?

The market cap of Cns Pharmaceuticals Inc is $3.1M.

What is the P/E of Cns Pharmaceuticals Inc?

The current P/E of Cns Pharmaceuticals Inc is null.

What is the EPS of Cns Pharmaceuticals Inc?

The EPS of Cns Pharmaceuticals Inc is -$1,943.50.

What is the PEG Ratio of Cns Pharmaceuticals Inc?

The PEG Ratio of Cns Pharmaceuticals Inc is null.

What do analysts say about Cns Pharmaceuticals Inc?

According to the analysts Cns Pharmaceuticals Inc is considered a buy.